STK11 and neoplasm: found that through the TIMER and TISIDB databases that infiltrating immune cells, including B cells, CD8 (+) T lymphocytes, CD4 (+) T lymphocytes, macrophages, and dendritic cells, were significantly reduced in patients with STK11 mutations, which indicate that patients carrying STK11 mutations might have a cold tumor immune microenvironment or immune desert type, and therefore could not benefit from immunotherapy (41, 42).